Following the May 10, 2021 approval from the Food and Drug Administration (FDA) authorizing the Pfizer COVID-19 vaccine for adolescents aged 12-15, approximately 17 million adolescents are now able to get vaccinated, about half of whom are adolescents of color. States are using lessons learned from earlier vaccination efforts and adapting the planning and implementation process of vaccinating individuals aged 16 and older against COVID-19 to inform the process for those 12 and older and ensure an equitable and efficient approach. This authorization raises new […]
Author Archive for: jill-rosenthal
About Jill Rosenthal
This author has yet to write their bio.Meanwhile lets just say that we are proud Jill Rosenthal contributed a whooping 4 entries.
Entries by Jill Rosenthal
Faced with limited vaccine supplies, a slow rollout of federal funds, and new federal guidelines allowing vaccination of those 65 and older, states face distribution challenges as they quickly evaluate which mass immunization practices are most effective.
As COVID-19 infections, hospitalizations and deaths soar and federal guidance evolves, states are finetuning their vaccine distribution plans as the US Food and Drug Administration (FDA) appears poised to approve a vaccine later this week. The timely, safe, and equitable distribution of the vaccines falls squarely on states and their providers, who are already stretched […]
As development of a COVID-19 vaccine continues, states are racing to develop vaccine distribution plans and are eager to ensure that the administrative challenges of testing and personal protective equipment distribution are not repeated. They must orchestrate vaccine storage and administration, data tracking, and capacity issues while questions about who will ultimately pay for the […]